1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cystic Fibrosis Global Clinical Trials Review, H2, 2016

Cystic Fibrosis Global Clinical Trials Review, H2, 2016

  • August 2016
  • -
  • Global Data
  • -
  • 456 pages

Cystic Fibrosis Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Cystic Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Cystic Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Cystic Fibrosis Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2


Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Cystic Fibrosis Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Cystic Fibrosis 30
Aug 16, 2016: Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura 30
Aug 15, 2016: Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis 30
Jul 15, 2016: Pharmaxis Completes Recruitment of Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market 31
Jul 07, 2016: Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis 31
Jul 07, 2016: Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis 32
Jun 21, 2016: ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC 32
Jun 10, 2016: Vertex Announces Presentation of Data for KALYDECO (ivacaftor) at European Cystic Fibrosis Society Conference 33
Jun 10, 2016: Vertex Announces Presentation of Data for ORKAMBI (lumacaftor/ivacaftor) at European Cystic Fibrosis Society Conference 34
Jun 10, 2016: Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR at the 39th European Cystic Fibrosis Conference 35
Jun 10, 2016: New Analyses from Phase 3 Study 009 of Translarna (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference 36
Jun 10, 2016: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference 36
Jun 07, 2016: Raptor Pharmaceutical to Present Data on QUINSAIR at European Cystic Fibrosis Conference 37
Clinical Trial Profile Snapshots 38
Appendix 453
Abbreviations 453
Definitions 453
Research Methodology 454
Secondary Research 454
About GlobalData 455
Contact Us 455
Disclaimer 455
Source 456

List of Tables
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region, 2016* 6
Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2016* 14
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2016* 17
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Cystic Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Cystic Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Cystic Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Cystic Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Cystic Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Cystic Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, G7 Countries (%), 2016* 14
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Cystic Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Cystic Fibrosis to Respiratory Clinical Trials, E7 Countries (%), 2016* 17
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Cystic Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Cystic Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Cystic Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Cystic Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Cystic Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Cystic Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Cystic Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Cystic Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Cystic Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 454

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.